Figure 2From: Predictors of primary breast cancers responsiveness to preoperative Epirubicin/Cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signaturesPLS discrimination according to tumor response class using the variables selected by PLS (VIP > 1.9) and ratio (pCR/NC) > 1.9 or < 0.55. Model 1 (PR cases were deleted; class 1 – pCR, black dots; class 2 – NC, black squares); 96 probe sets (cDNAs) retained.Back to article page